BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25224410)

  • 1. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
    Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
    Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin in the treatment of CD30+ PTCL.
    Barta SK; Gong JZ; Porcu P
    Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas.
    Karube K; Kakimoto Y; Tonozuka Y; Ohshima K
    Expert Rev Hematol; 2021 Aug; 14(8):777-787. PubMed ID: 34263699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
    Nizamuddin I; Galvez C; Pro B
    Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.
    Lamarque M; Bossard C; Contejean A; Brice P; Parrens M; Le Gouill S; Brière J; Bouabdallah R; Canioni D; Tilly H; Bouchindhomme B; Bachy E; Delarue R; Haioun C; Gaulard P
    Haematologica; 2016 Mar; 101(3):e103-6. PubMed ID: 26703966
    [No Abstract]   [Full Text] [Related]  

  • 8. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.
    Bisig B; de Reyniès A; Bonnet C; Sujobert P; Rickman DS; Marafioti T; Delsol G; Lamant L; Gaulard P; de Leval L
    Haematologica; 2013 Aug; 98(8):1250-8. PubMed ID: 23716562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
    Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.
    Schönberger S; van Beekum C; Götz B; Nettersheim D; Schorle H; Schneider DT; Casati A; Craveiro RB; Calaminus G; Dilloo D
    J Cell Mol Med; 2018 Jan; 22(1):568-575. PubMed ID: 28941150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High intratumoural galectin-1 expression predicts adverse outcome in ALK
    Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
    Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
    Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
    J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma.
    Debliquis A; Baseggio L; Bouyer S; Guy J; Garnache-Ottou F; Genevieve F; Mayeur-Rousse C; Letestu R; Chapuis N; Harrivel V; Bennani H; Lachot S; Loosveld M; Nicolino-Brunet C; Pérès M; Roussel M; Veyrat-Masson R; Jacob MC; Drenou B
    Cytometry B Clin Cytom; 2021 Jul; 100(4):488-496. PubMed ID: 32803917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.
    Boddicker RL; Kip NS; Xing X; Zeng Y; Yang ZZ; Lee JH; Almada LL; Elsawa SF; Knudson RA; Law ME; Ketterling RP; Cunningham JM; Wu Y; Maurer MJ; O'Byrne MM; Cerhan JR; Slager SL; Link BK; Porcher JC; Grote DM; Jelinek DF; Dogan A; Ansell SM; Fernandez-Zapico ME; Feldman AL
    Blood; 2015 May; 125(20):3118-27. PubMed ID: 25833963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.